Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zavegepant intranasal pharmacokinetics study comparing patient-centric vs. venous blood sampling
NCT05948085Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zavegepant in migraine, sponsored by Pfizer. Primary endpoints: Plasma Concentration of Zavegepant at 30 Minutes Post-dose, Plasma Concentration of Zavegepant at 1 Hour Post-dose and 11 more. Started Jul 2023; status: completed.
02
Drugs
zavegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05948085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05948085.